A novel approach to measure the contribution of matrix metalloproteinase in the overall net proteolytic activity present in synovial fluids of patients with arthritis

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Simard, Nathalie ^a   Boire, Gilles ^b   de Brum Fernandes, Artur J ^b   St Pierre, Yves ^a  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLLAGENASE; GELATINASE B; PEPTIDE HYDROLASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTHRITIS; BLOOD; ENZYMOLOGY; FLOW CYTOMETRY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE; METABOLISM; OSTEOARTHRITIS; PATHOLOGY; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SYNOVIAL FLUID;

ARTHRITIS; ARTHRITIS, JUVENILE; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; COLLAGENASES; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; MATRIX METALLOPROTEINASE 9; OSTEOARTHRITIS; PEPTIDE HYDROLASES; SPONDYLARTHROPATHIES; SYNOVIAL FLUID; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 70350591576     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2014     Document Type: Article

References (45)

1. Momohara S, Kashiwazaki S, Inoue K, Saito S, Nakagawa T: Elastase from polymorphonuclear leukocyte in articular cartilage and synovial fluids of patients with rheumatoid arthritis. Clin Rheumatol 1997, 16:133-140.
2. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ: Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996, 39:1576-1587.
3. Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000, 59 455-461.
4. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP: Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: Comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003, 62 635-638.
5. Close DR: Matrix metalloproteinase inhibitors in rheumatic diseases Ann Rheum Dis 2001, 60(Suppl 3):iIi62-67.
6. Elliott S, Cawston T: The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging 2001, 18:87-99.
7. Vu TH, Werb Z: MatrixEmetalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123-2133.
8. St-Pierre Y, Van Themsche C: Matrix metalloproteinases in the inflammation of the lung. In Proteases in Tissue Remodelling of Lung and Hearts Edited by: Lendeckel U. New York: Kluwer Academic Publishing; 2004:35-56.
9. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR: Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:2503-2511.
10. Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, et al.: Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998, 41:110-121.
11. Clements KM, Price JS, Chambers MG, Visco DM, Poole AR, Mason RM: Gene deletion of either interleukin-1βeta, interleukin- 1βeta-converting enzyme, inducible nitric oxide synthase, or stromelysin 1 accelerates the development of knee osteoarthritis in mice after surgical transection of the medial collateral ligament and partial medial meniscectomy. Arthritis Rheum 2003, 48:3452-3463.
12. van Bilsen JH, Wagenaar-Hilbers JP, Grosfeld-Stulemeijer MC, van der Cammen MJ, van Dijk ME, van Eden W, Wauben MH: Matrix metalloproteinases as targets for the immune system during experimental arthritis. J Immunol 2004, 172:5063-5068.
13. Ribbens C, Andre B, Kaye O, Kaiser MJ, Bonnet V, Jaspar JM, De Groote D, Franchimont N, Malaise MG: Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not Rheumatology (Oxford) 2000, 39:1357-1365.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
15. Esteve PO, Chicoine E, Robledo O, Aoudjit F, Descoteaux A, Potworowski EF, St-Pierre Y: Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-alpha in glioma cells via NF-kappa B. J Biol Chem 2002, 277:35150-35155.
16. St-Pierre Y, Desrosiers M, Tremblay P, Esteve PO, Opdenakker G: Flow cytometric analysis of gelatinase B (MMP-9) activity using immobilized fluorescent substrate on microspheres. Cytometry 1996, 25:374-380.
17. Kitano T, Ohashi H, Kadoya Y, Kobayashi A, Yutani Y, Yamano Y: Measurement of ζ potentials of particulate biomaterials in protein- rich hyaluronan solution with changes in pH and protein constitutents J Biomed Mater Res 1998, 42:453-457.
18. Ward TT, Steigbigel RT: Acidosis of synovial fluid correlates with synovial fluid leukocytosis. Am J Med 1978, 64:933-936.
19. Champagne B, Tremblay P, Cantin A, St Pierre Y: Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J Immunol 1998, 161 6398-6405.
20. Robinson AD, Boyden KN, Hendrickson SM, Muirden KD: Antitrypsin activity and enzyme inhibitors in the rheumatoid joint. J Rheumatol 1981, 8:547-554.
21. Fuchs S, Skwara A, Bloch M, Dankbar B: Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthritis Cartilage 2004, 12:409-418.
22. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD: Interleukin 17 induces cartilage collagen breakdown: Novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 2002, 61:704-713.
23. Wolfe F: The C reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. J Rheumatol 1997, 24 1486-1488.
24. Jovanovic DV, Martel-Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Benderdour M, Pelletier JP: Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: A possible role in rheumatoid arthritis. Arthritis Rheum 2000, 43:1134-1144.
25. Makowski GS, Ramsby ML: Zymographic analysis of latent and activated forms of matrix metalloproteinase-2 and -9 in synovial fluid: correlation to polymorphonuclear leukocyte infiltration and in response to infection. Clin Chim Acta 2003, 329:77-81.
26. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, et al.: Discovery of potent, achiral matrix metalloproteinase inhibitors. J Med Chem 1998, 41:3568-3571.
27. Borden P, Solymar D, Sucharczuk A, Lindman B, Cannon P, Heller RA: Cytokine control of interstitial collagenase and collagenase- 3 gene expression in human chondrocytes. J Biol Chem 1996, 271 23577-23581.
28. Vincenti MP, Coon CI, Mengshol JA, Yocum S, Mitchell P, Brinckerhoff CE: Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: Differential expression with collagenase-1 (matrix metalloproteinase-1). Biochem J 1998, 331:341-346.
29. Nordstrom D, Lindy O, Konttinen YT, Lauhio A, Sorsa T, Friman C, Pettersson T, Santavirta S: Cathepsin G and elastase in synovial fluid and peripheral blood in reactive and rheumatoid arthritis. Clin Rheumatol 1996, 15:35-41.
30. Ishiguro N, Ito T, Oguchi T, Kojima T, Iwata H, Ionescu M, Poole AR: Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:2503-2511.
31. Cawston T: Matrix metalloproteiPases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today 1998, 4:130-137.
32. Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T, Emery P, Poole AR, Veale DJ: Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: Relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003, 48:3085-3095.
33. Punzi L, Calo L, Plebani M: Clinical significance of cytokine determination in synovial fluid. Crit Rev Clin Lab Sci 2002, 39:63-88.
34. Hegemann N, Kohn B, Brunnberg L, Schmidt MF: Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders Osteoarthritis Cartilage 2002, 10:714-721.
35. Bazzichi L, Ciompi ML, Betti L, Rossi A, Melchiorre D, Fiorini M, Giannaccini G, Lucacchini A: Impaired glutathione reductase activity and levels of collagenase and elastase in synovial fluid in rheumatoid arthritis. Clin Exp Rheumatol 2002, 20:761-766.
36. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE: Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase- 13 from human osteoarthritic cartilage. J Clin Invest 1996, 97:761-768.
37. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, et al.: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997, 99:1534-1545.
38. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ: Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996, 380:17-20.
39. Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H: Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J Biol Chem 2000, 275:33008-33013.
40. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G, et al.: Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002, 110:1419-1427.
41. Peake NJ, Khawaja K, Myers A, Jones D, Cawston TE, Rowan AD, Foster HE: Levels of matrix metalloproteinase (MMP)-1 in paired sera and synovial fluids of juvenile idiopathic arthritis patients: Relationship to inflammatory activity, MMP-3 and tissue inhibitor of metalloproteinases-1 in a longitudinal study. Rheumatology 2005, 44:1383-1389.
42. Gueders MM, Balbin M, Rocks N, Foidart JM, Gosset P, Louis R, Shapiro S, Lopez-Otin C, Noel A, Cataldo DD: Matrix metalloproteinase- 8 deficiency promotes granulocytic allergen-induced airway inflammation J Immunol 2005, 175:2589-2597.
43. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM: Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 2002, 100 1160-1167.
44. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark- Lewis I, Overall CM: Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001, 276:43503-43508.
45. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF- 4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000, 96 2673-2681.